(NU/1433-47) Kargenera: The Provision of Business Consultancy to Assist Commercialisation of University Research
The University of Southampton have developed a unique DNA based therapeutic to activate NK cells against cancer. The therapeutic is delivered intramuscularly in combination with DNA encoding the potent immune stimulating cytokine IL-15. The objective is for an Executive to jointly work with the team to bring the opportunity towards and ultimately achieve launch of a new spinout company.
Buyer
NEWCASTLE UNIVERSITY
Value
£30,000
Published
6 Feb 2023
Closes
6 Feb 2023
Procurement details
Source
Find a Tender
Region
United Kingdom
Procurement method
Selective
Category
Services
Contract starts
Not provided
Contract ends
Not provided
CPV classifications
79400000
Business and management consultancy and related services
Lots
Lot 1 (NU/1433-47) Kargenera: The Provision of Business Consultancy to Assist Commercialisation of University Research
£30,000
The project description is included below: Phase 1 Opportunity Validation and Business Plan Creation - Executive leads all activity; ensures other team members support on relevant technical/ application needs inputs; if requested by Exec, UoS R&IS department will assist defining business plan requirements Phase 2 Research organisation Approval In Principle t...
Delivery: North East (England)
Documents
No document metadata is available for this public record.
Contains public sector information licensed under the Open Government Licence v3.0.